An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.
A drug that binds to iron and that has been FDA-approved for treating other conditions has shown promise in treating ovarian cancer in mouse models. Researchers are now designing human trials for the ...
Iron-chelating drugs bind tightly to iron, preventing cells from using it. To confirm the importance of iron in ovarian cancer, Dr. Cubillos-Ruiz's team first looked at a collection of human tumor ...
CHELATION THERAPY HAS been around for decades as a treatment for toxic metal poisoning. But, there have also been claims that the therapy could help several other conditions. Experts aren't so sure.
The global Iron Chelation Drug market was valued at 4433.91 Million USD in 2020 and will grow with a CAGR of 4.33% from 2020 to 2027, based on Report Ocean newly published report. The file offers ...
Longitudinal survey data from Mexico suggested that a so-called weekend warrior physical activity pattern was associated with a reduced risk of mild dementia. (British Journal of Sports Medicine) Also ...
Researchers at the University of São Paulo (USP) in Brazil have discovered that two osteoporosis drugs (etidronate and tiludronate) may combat diseases caused by iron accumulation in the body. In ...
Researchers at the University of São Paulo (USP) in Brazil have discovered that two osteoporosis drugs (etidronate and tiludronate) may combat diseases caused by iron accumulation in the body. In ...
An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results